Clinigen GAP - how we work
Clinigen GAP specializes in the consultancy, development, management and implementation of Global Access Programs for biotechnology and pharmaceutical companies.
Our innovative, bespoke programs provide a fully outsourced solution for managing access to unlicensed, licensed or end of lifecycle products.
We understand the value of products to a company and the importance of protecting and maximizing the long-term value of assets through Global Access Programs.
Our highly dedicated, multilingual and experienced team effectively manages client and product needs. We have proven management experience of implementing over 30 programs, providing access for thousands of patients globally.
More detail about Clinigen GAP's programs:
Early Access Programs
We manage provision of pre-license/pre-launch medicines to patients with unmet medical needs by creating tailored Named Patient Programs or Expanded Access Programs in the USA. Early Access Programs also include access solutions to medicines for patients exiting clinical trials through Clinical Trial Aftercare and Compassionate Use Programs.
Commercial Access Programs
We provide solutions to biopharmaceutical companies looking for specialist Commercial Patient Access Schemes or Bespoke Access Programs to facilitate successful commercialization strategies.
Mature Product Access Programs
We provide solutions for pharmaceutical and biotechnology companies to continue to make products which are withdrawn, discontinued or reaching the end of their lifecycle accessible to patients.